ISIS 2302, an antisense inhibitor of intercellular adhesion molecule 1.

Area of Science:

• Immunology
• Pharmacology
• Molecular Biology

Background:

• Intercellular Adhesion Molecule 1 (ICAM-1) plays a critical role in inflammatory diseases and transplant rejection.
• ISIS 2302 is a novel antisense oligodeoxynucleotide designed to inhibit ICAM-1 expression.

Purpose of the Study:

• To evaluate the safety, pharmacokinetics, and efficacy of ISIS 2302 in various inflammatory conditions and transplantation models.
• To assess the potential of ISIS 2302 as a therapeutic agent for autoimmune and inflammatory diseases.

Main Methods:

• Phase I, IIa, and pivotal quality clinical trials involving intravenous administration of ISIS 2302.
• Pharmacokinetic studies in animals and humans to determine drug distribution and elimination.
• Dose-ranging studies (0.06 - 2 mg/kg) and placebo-controlled trials in patients with Crohn's disease, rheumatoid arthritis, psoriasis, and renal allograft rejection.

Main Results:

• ISIS 2302 demonstrated favorable pharmacokinetics with longer tissue elimination half-lives (1-5 days) compared to plasma half-life (30-60 min).
• Well-tolerated in Phase I studies, with no clinically significant adverse events reported.
• Showed durable remission-inducing and steroid-sparing properties in Crohn's disease patients.
• Modest efficacy and excellent tolerability observed in rheumatoid arthritis and psoriasis trials.

Conclusions:

• ISIS 2302 exhibits significant therapeutic potential for inflammatory diseases, particularly Crohn's disease, due to its ICAM-1 inhibitory mechanism.
• The compound is well-tolerated and demonstrates durable clinical benefits, supporting further development.
• Ongoing and planned trials will further elucidate its efficacy in various formulations and indications.